GLP-1 insurance coverage in 2026: what gets covered, what gets denied
Your plan document sets coverage, and two plans from the same insurer often differ. 43 percent of employers with 5,000 or more workers cover a GLP-1 for obesity, Medicare covers two specific indications, 19 state Medicaid programs cover it for obesity, and everyone else pays cash from about $149 a month.
Every coverage path at a glance
| Coverage path | Typical out-of-pocket / mo | What unlocks it | Source |
|---|---|---|---|
| Commercial, obesity-covered plan | $25 to $100 copay | Approved PA + step therapy or comorbidity | KFF employer survey |
| Commercial, T2D coverage | $25 to $80 copay | A1c above 6.5 + ICD-10 E11.x | ADA Standards |
| Medicare Part D, Wegovy CV | $50 to $200 copay | Established CV disease + BMI 27+ | CMS Part D |
| Medicare Part D, Zepbound OSA | $50 to $200 copay | AHI 15+ + BMI 30+ | Zepbound OSA approval |
| FEHB FEP Blue (federal employees): coverage details | Tier 2 to 3 copay (plan-dependent) | OPM mandate + PA (BMI 30+ or 27+ with comorbidity) | OPM FEHB mandate |
| Medicaid, T2D path | $0 to $8 copay | State formulary + PA | State-by-state breakdown |
| Medicaid, obesity path | $0 to $8 copay (19 states) | State formulary + PA | State-by-state breakdown |
| HSA / FSA, any path | Tax savings 25 to 40% | Prescription + receipts | IRS Pub 502 |
The KFF employer survey is the reference for commercial coverage rates. We update the state Medicaid breakdown quarterly and on every major state PDL change.
How commercial insurance covers GLP-1
Commercial plans land in one of three patterns: covered for obesity with prior authorization the approval an insurer requires before it will pay for the drug, covered for type 2 diabetes only, or obesity brands excluded entirely.
- Coverage tracks employer size. 43 percent at firms with 5,000+ workers, up from 28 percent a year earlier, about 30 percent at 1,000 to 4,999, and 16 percent at 200 to 999 (KFF 2025). KFF does not survey below 200 employees, and smaller firms likely sit lower.
- Read the formulary, not the policy page. The formulary the list of drugs your plan will pay for, published by your insurer or PBM is plan-level. Many UnitedHealthcare commercial plans cover Wegovy. Some UnitedHealthcare employer plans carve out anti-obesity medication entirely. Both are “UnitedHealthcare.”
- Payer-by-payer, with the published policy citation for each: does my insurance cover Wegovy or Zepbound, including the Wellcare Medicare GLP-1 coverage page. Plan-specific templates are in the PA letter library.
The prior authorization process, step by step
Every commercial plan that covers a GLP-1 for obesity requires prior authorization. The review window runs 72 hours to 7 business days. Your prescriber submits the form with documentation, the insurer's PBM pharmacy benefit manager scores it against policy criteria, and the insurer returns an approval, a denial, or a request for more information. A denial leaves 180 days to appeal. Templates and the filing workflow are in the PA letter library.
What documentation the PA needs
Documentation decides the PA. Most plans require all of this:
- BMI documented within the past 30 days (height and weight)
- Comorbidity diagnosis with the correct ICD-10 code (the numeric billing code that tells the insurer your diagnosis):
- E66.01 for morbid obesity
- I10 for hypertension
- E78.x for dyslipidemia
- G47.33 for sleep apnea
- E11.x for type 2 diabetes
- Six months of documented lifestyle intervention (dietitian notes, MyPlate logs, or a structured program)
- Prior anti-obesity medication trial or documented contraindication (phentermine, orlistat, naltrexone-bupropion, liraglutide)
- Treatment plan with target weight loss and monitoring schedule
PCOS patients
PCOS patients who meet the BMI threshold qualify on the obesity-with-comorbidity path. File under E66.9 (obesity) plus R73.03 (prediabetes) plus E28.2 (PCOS) as supporting context. Filing under E28.2 alone will be denied.
Common denial reasons and how to overturn them
Six categories cover almost every GLP-1 denial. The appeal letter library has plan-specific templates for the most-cited ones, each with the trial evidence and policy citation that supports the appeal.
- Step therapy not met. The most common denial, and the most overturnable when there is a documented contraindication or intolerance to the step-therapy drug the less expensive drug the insurer requires you to try before approving the more expensive one.
- No lifestyle intervention documented. Second most common.
- BMI below threshold at the time of submission.
- No comorbidity documentation, or a comorbidity without its ICD-10 code.
- Formulary exclusion. The plan does not list the drug at all.
- Not medically necessary, the catch-all a PBM reviewer applies when a criterion is unchecked.
The four appeal pathways
The Affordable Care Act and ERISA (the federal law governing employer health plans) give you four appeal paths, in order. Templates for each denial reason are in the appeal letter library.
- Peer-to-peer review. The prescriber calls the insurer's medical director. Often 5 business days, informal, and frequently successful when the prescriber frames the trial evidence clinically. No GLP-1-specific overturn rate is published.
- First-level internal appeal. Written. The insurer must respond within 30 days, or 72 hours if expedited. About 44 percent of appealed denials in ACA marketplace plans were reversed in 2023 across all drug and service categories (KFF).
- External review by an IRO (Independent Review Organization, a third-party reviewer the insurer cannot influence). Required under the ACA for medical-necessity denials, free to you, and binding on the insurer.
- State insurance commissioner complaint. Slower and less likely to overturn. Use it when the denial applies a criterion that is not in the published policy.
Medicaid coverage state by state
Federal policy lets states cover anti-obesity medication. It does not require it. 19 state Medicaid programs cover Wegovy or Zepbound for obesity with prior authorization. The other 32 cover only the diabetes brands (Ozempic, Mounjaro), and only for type 2 diabetes.
- California Medi-Cal dropped obesity-indication GLP-1 from its preferred drug list in mid-2025. Massachusetts and Pennsylvania expanded coverage the same year.
- PA criteria, formulary status and submission contacts for every state are at Medicaid GLP-1 coverage by state, for example Minnesota and Indiana.
- Medicaid managed care adds steps. Check your assigned MCO's formulary before filing.
Medicare Part D coverage
Part D excludes drugs for weight loss under the 2003 Medicare Modernization Act. Four routes get around that.
- Wegovy for cardiovascular risk reduction. Adults with established cardiovascular disease and BMI 27+, following the SELECT registration trial (NEJM, November 2023). Labeled March 2024.
- Zepbound for moderate-to-severe obstructive sleep apnea. Adults with obesity, following SURMOUNT-OSA. Labeled December 2024. See Wegovy and Zepbound OSA coverage.
- The Medicare GLP-1 Bridge, live since July 1, 2026. A CMS demonstration running through December 31, 2027. It furnishes Wegovy, Foundayo and the Zepbound KwikPen at a flat $50 a month, for weight-management prescriptions only, to Part D beneficiaries who meet the clinical criteria (BMI 35+, or BMI 30+ with heart failure with preserved ejection fraction, uncontrolled high blood pressure or stage 3a or worse kidney disease, or BMI 27+ with pre-diabetes, a past heart attack or stroke, or peripheral artery disease with symptoms). It sits outside Part D, so no deductible applies and the copay does not count toward out-of-pocket totals. Costs by indication are in the Medicare GLP-1 cost guide.
- Medicare Advantage supplemental benefits. A few MA plans cover anti-obesity medication beyond Part D. The Wellcare Medicare GLP-1 coverage page shows plan-specific CV and OSA criteria, and the senior overview walks the whole decision.
Military families have their own path. TRICARE covers Wegovy and Zepbound for weight management with prior authorization on TRICARE Prime and Select. TRICARE For Life and the non-Prime plans exclude weight-loss drugs. Rules and the cost caveat are on the TRICARE GLP-1 coverage page.
Employer-sponsored plans and self-funded carve-outs
- Fully-insured plans use the insurer's standard formulary. If Aetna covers Wegovy commercially, an Aetna fully-insured employer plan covers Wegovy.
- Self-funded plans where the employer bears the claim cost and the insurer only administers claims often carve out anti-obesity medication to control cost. The carve-out shows on the plan's summary plan description (SPD). If the SPD lists anti-obesity medication as “not covered,” PA is futile, and the appeal goes to the employer benefits committee, not the insurer.
HSA, FSA and HRA
All three can pay for a GLP-1 with a prescription under IRS Publication 502, for branded and compounded medication alike, and for the membership fee at a licensed telehealth program. A $400 a month cash program costs about 33 percent less paid from an HSA. That assumes a 24 percent federal bracket, 5 percent state tax and FICA savings.
When your insurance changes
Open enrollment, a job change and ACA marketplace re-enrollment all break coverage. On a stable dose you can request a continuity-of-care exception under the new plan, typically 60 to 90 days, while the new PA is processed. Send it with the prior PA approval letter and a clinical note showing current dose and response. If the new plan covers no GLP-1 at all, the exception buys time to set up a cash-pay or manufacturer-direct path.
Payer-specific PA templates
Every template in the PA letter librarycarries the payer's own policy citation, its documentation checklist, its submission instructions, and the language we have seen overturn denials. File under the right criteria set: a T2D request under the diabetes-brand criteria, an obesity request under the obesity-brand criteria, a CV-risk request under the SELECT language.
- Where coverage is employer-elected, confirm the benefit exists before filing. Premera Blue Cross coverage for Wegovy and Highmark coverage for Wegovy and Zepbound (including the sleep apnea pathway) both turn on employer election.
- Where the plan dropped the drug outright, the filing is a formulary exception, not a standard PA, and the plan usually demands a documented step-through of the preferred agent first. Aetna Zepbound coverage is the worked example: non-formulary on the standard commercial plan series since July 1, 2025 under exception policy 6981-A, still covered with prior authorization on FE-Compatible plans under policy 6947-C.
- ACA marketplace: ACA marketplace GLP-1 coverage. Regional plans: Independence Blue Cross GLP-1 coverage, which carries detailed PA criteria. Federal employees: FEHB Blue Cross coverage for Wegovy and Zepbound.
How insurers decide
Insurers do not read the medical record from the top. The PBM clinical reviewer, usually a PharmD or an RN, runs the submission against a checklist drawn from the insurer's policy bulletin. Every box checked is an approval. One box unchecked escalates or is denied. The PA is a criteria match, so save the narrative argument for the appeal letter.
Off-label and uncovered indications
A GLP-1 prescribed for PCOS, NAFLD or alcohol use disorder is off-label in 2026 and almost always denied by commercial insurance. If you also qualify for a covered indication (obesity with comorbidity, T2D, or CV risk reduction), ask your prescriber to file under that one. NAFLD strategy: Zepbound and MASH.
Trial evidence and policy citations
The registration trials PA letters most often cite, in order of frequency:
- STEP-1 (Wegovy, NEJM 2021) for the obesity indication
- SURMOUNT-1 (Zepbound, NEJM 2022) for the obesity indication
- SELECT (Wegovy, NEJM 2023) for cardiovascular risk reduction
- SURMOUNT-OSA (Zepbound, NEJM 2024) for the sleep apnea indication
- FLOW (Ozempic, NEJM 2024) for the renal indication
- SURPASS (tirzepatide for T2D, NEJM and Lancet 2022 to 2023)
The federal external-review process is documented at healthcare.gov external review, and ERISA-plan appeal rules at the Department of Labor EBSA.
What to do next
- Commercial insurance: start with the payer-specific PA template. Already denied? Match the denial reason to its appeal template and open with peer-to-peer review.
- Medicare: the path is indication-dependent, Wegovy for CV risk or Zepbound for OSA, with the Bridge at $50 a month if you meet the criteria.
- Medicaid: start at your state's page.
- Covered, but the copay is high: a manufacturer savings card cuts a commercial copay to as low as $25 a month. Every card is in the coupons and savings guide, alongside the NovoCare and LillyDirect cash programs and the Medicare Bridge.
- Plan excludes GLP-1s outright: the fastest path is cash-pay compounded semaglutide. The cost pillar and the program chart carry every cash route.
- Programs that bill commercial insurance and coordinate prior authorization: Noom Med, Found, Knownwell, Calibrate (requires commercial insurance, about $224 a month all-in), WeightWatchers Clinic (about $99 a month with coverage) and Amazon Pharmacy (branded Wegovy and Zepbound at upfront cash prices, and with eligible insurance the oral pill can drop to $25 a month). Mochi Health, Henry Meds, Hims and Ro are cash-pay only for the medication.
Frequently asked questions
Does insurance cover Wegovy or Zepbound for weight loss?
Most commercial plans either cover both, cover one with a step-therapy hurdle, or cover neither for obesity. Coverage is plan-specific, not insurer-wide. UnitedHealthcare covers Wegovy on most commercial plans but excludes it from many employer carve-outs. Anthem coverage varies by state affiliate. The only way to know is to check your plan's formulary, not your insurer's general policy.
How long does prior authorization take?
Standard PA review windows run 72 hours (Cigna) to 5-7 business days (Aetna, UnitedHealthcare, Anthem). Expedited PA, requested when delay would cause clinical harm, is 24 to 72 hours. Most denials hit within the standard window. No published benchmark exists for GLP-1 first-pass approval rates; complete documentation is the strongest factor a patient controls.
What is the most common reason GLP-1 prior auths are denied?
Step therapy not met (the patient has not tried phentermine, orlistat or another preferred agent first) is the single most common denial. Insufficient documentation of six-month lifestyle intervention is second. BMI below the threshold or comorbidity not documented with an ICD-10 code is third. All three are reversible on appeal with the right documentation.
Can I appeal a denial?
Yes, and the appeal rate of GLP-1 denials is higher than for most drug categories. There are four appeal pathways: peer-to-peer review with the plan's medical director, formal first-level internal appeal, external review by an independent reviewer, and state insurance commissioner complaint. The first two are run by the insurer; the second two are run by a third party. In ACA marketplace plans, 44 percent of appealed denials were reversed in 2023 across all categories (KFF); structuring the appeal around the trial-evidence base improves the odds.
Does Medicare cover GLP-1 for weight loss?
Medicare Part D does not cover any drug for weight loss, under a 2003 federal statute. Wegovy is covered for cardiovascular risk reduction in patients with established cardiovascular disease (since March 2024). Zepbound is covered for moderate-to-severe obstructive sleep apnea with BMI 30 or above (since December 2024). Both require the specific indication, not the obesity label. Separately, from July 1, 2026 through December 31, 2027, the Medicare GLP-1 Bridge demonstration furnishes Wegovy, Foundayo and the Zepbound KwikPen at a flat $50 a month to Part D beneficiaries who meet CMS clinical criteria. It covers weight-management prescriptions only and operates outside the Part D benefit.
Does Medicaid cover GLP-1?
19 state Medicaid programs cover Wegovy or Zepbound for obesity, always with prior authorization. The remaining 32 cover only the diabetes brands (Ozempic, Mounjaro) for patients with type 2 diabetes. Every state's status and the policy citation behind it live on the medicaid-by-state pages.
Can I use HSA or FSA money for GLP-1?
Yes. GLP-1 prescribed by a licensed provider is an eligible medical expense for HSA, FSA, and HRA accounts. This applies to both branded and compounded medication, and to the program membership fee when the program is a licensed medical practice. Save the receipts; the documentation is usually a Letter of Medical Necessity from the prescriber.
What happens if my employer changes insurance plans mid-year?
Coverage continuity is the patient's responsibility. Most plans accept a continuity-of-care exception for 60 to 90 days if the new plan would otherwise deny PA on a drug the patient was stable on under the prior plan. Submit the exception request with the prior PA approval and a clinical note documenting current dose and response.
Does the appeal process cost anything?
Internal appeals (with the insurer) are free. External review by an Independent Review Organization (IRO) is also free to the patient under the Affordable Care Act; the insurer pays the IRO fee. State insurance commissioner complaints are free. The only real cost of the appeal cascade is time: roughly 30 to 90 days from denial to external review decision.
Which GLP-1 telehealth programs accept insurance?
Of the 27 GLP-1 telehealth programs GLP Chart tracks, 7 accept commercial insurance billing: Noom Med, Found, Calibrate, WeightWatchers Clinic, 9amHealth, Knownwell, Amazon Pharmacy. Calibrate requires commercial insurance and runs about $224/mo all-in with medication billed to your plan. Mochi Health, Henry Meds, Hims, and Ro are cash-pay only for the medication. Programs that accept insurance coordinate prior authorization on your behalf and bill the GLP-1 medication to your plan, so you pay your plan's copay. We cannot publish that number because your plan sets it.
